Strategic Regulatory & Drug Development Consulting

Navigate FDA and EMA pathways with confidence. Our expert consultants provide end-to-end regulatory strategy and clinical development guidance for biotech and pharma.
From early drug development to marketing authorization, Ergomed Consulting minimizes regulatory risk. We offer tailored strategies for orphan drug designations, pediatric investigation plans (PIPs), and scientific advice meetings. Our global team ensures your submission strategy aligns with both US and European requirements for a smooth market entry.

Global Regulatory Expertise, Local Market Insight

At Ergomed Consulting, we bring a unique combination of global regulatory affairs consulting and local market insight to accelerate your clinical development.

With decades of experience in pharmaceutical regulatory consulting services, our team includes former FDA and EMA regulators, KOLs, and industry experts. This diverse regulatory and clinical expertise enables us to guide sponsors through complex international requirements while remaining aligned with evolving regional expectations.

Ergomed Consulting Services Include:

Ergomed Consulting
  • Our clinical development consultants support early strategic planning, indication prioritization, and gap analysis. By aligning clinical programs with regulatory expectations, we streamline pathways to trials and maximize early-stage success

Multidisciplinary Regulatory Expertise to Accelerate Success

Across every phase of the product lifecycle, Ergomed Consulting experts elevate your product viability–from shortened pathways to trial to regulatory agility and compliance, expedited global entry to sustained competitive edge. It’s what we do.

KOLs, Former Regulators, Expert Strategists
Complex Diseases and Novel Therapies
End-to-End Drug Development Advisory
Flexible Model and Bespoke Service
Global Perspective Combined with Local Insight

Ergomed Consulting Solutions

Ergomed Consulting

Ergomed Consulting delivers expert, customized regulatory consulting for clinical trials across the entire drug development lifecycle—from discovery and preclinical planning to regulatory submission and post-market management. With deep therapeutic knowledge, former regulators, and cross-functional CRO integration, we equip sponsors with the insight and support needed to move forward—confidently and compliantly—at every milestone.

Discovery & Preclinical Phase

In the early stages of drug development, companies often face significant challenges such as funding gaps, complex regulatory landscapes, and translational hurdles that can delay progress.

Clinical Research (Phases I–III)

Clinical development is often complicated by complex protocols, regulatory barriers, and fragmented market access strategies.

Market Application & Regulatory Review

During the market application and regulatory review phase, companies must navigate a complex regulatory framework, minimize the risk of submission delays, as well as disparate review and approval process.

Post-Market Safety & Lifecycle Management

Following market approval, evolving safety expectations, increasing demands for evidence generation, and lifecycle competition present ongoing challenges.

Strategic Pre-IND Consulting for Gene Therapy in Rare Leukemia

Early Stage Development in Rare Pediatric Oncology

Market Approval for a Novel Non-Hodgkin Lymphoma (NHL) Therapy

Post-Market Safety & Risk Management in Duchenne Muscular Dystrophy (DMD)

Team Member Spotlight: 


Nan Shao, Executive Vice President of Ergomed Consulting

Our Executive Vice President of Ergomed Consulting, Nan Shao, brings over two decades of strategic and operational leadership in drug development. With a strong foundation as a trained statistician and extensive experience in both pharmaceutical and CRO settings, Nan has successfully led initiatives spanning the entire drug development lifecycle across diverse therapeutic areas.

Her expertise encompasses scientific rigor and operational excellence, empowering stakeholders through strategic use of data, optimized trial strategies, and patient-centric innovations. Nan is recognized for building collaborative, consultative partnerships that drive meaningful outcomes for clients and advance patient care.

In her role, Nan continues to shape the strategic direction of Ergomed Consulting by integrating data-driven insights, scientific innovation, and a steadfast commitment to improving healthcare outcomes.

Navigate the Complexities of the Entire Drug Development Path with Ergomed Consulting

At Ergomed Consulting, we simplify the complex with trusted regulatory consulting for clinical trials that spans the entire drug development lifecycle.

From early-stage planning to regulatory approval and post-market safety, our multidisciplinary team delivers integrated medical, scientific, statistical, and regulatory guidance tailored to your asset.

Whether you’re advancing a first-in-class therapy or refining a late-stage asset, our global regulatory affairs consulting helps you reduce risk, accelerate timelines, and bring safe, effective therapies to patients—worldwide.

Unparalleled Expertise,
Ergo, Flawless Execution

Contact Us

Our Complementary Services

See how Ergomed can support your clinical trial.

More Ergomed Services

Find out how Ergomed supports your clinical trial objectives.